Form 4: Achieve Life Sciences Executive Granted Stock Options

Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences, was granted 30,000 stock options on December 6, 2024.

Summary

• Jaime Xinos, the Chief Commercial Officer of Achieve Life Sciences, was granted 30,000 stock options.
• The options have an exercise price of $4.52 per share.
• The options vest 25% on the first anniversary of the grant date, December 6, 2024, and the remaining 75% vest in monthly installments over the following 36 months.
• The options expire on December 6, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder value if the executive's performance leads to company growth.

Key Dates

Keywords

stock options, executive compensation, insider trading, vesting, Achieve Life Sciences, ACHV, Jaime Xinos